Areas of Focus
Revolutionary medicines enable us to enrich and extend life for people living with all types of diseases.

Highlights
This is our rallying cry as our scientists relentlessly pursue breakthroughs that will change patients’ lives.
2023
Science
Will Win
"There are so many losers. They’re everywhere. Doubt, fear, sorrow. They lose.” This is what happens when science wins."
Clinical Trials
We proudly partner with thousands of study sites and tens of thousands of trial participants around the world. It’s these clinical trials that lead to life-changing medicines.
Go to Pfizer Clinical Trials Site Details
Learn more about the process of joining a clinical trial and find a trial near you.
Diseases & Conditions Index
Explore all of our disease and condition-related resources to learn more about your diagnosis and treatment options.
Search for a Disease or Condition DetailsPartnerships
Fellow organizations actively researching bold scientific ideas, capabilities, and technologies partner with us to bring innovative treatments to patients in need. And we continually seek new partnerships in several key interest areas.
Learn About Our Partners Details- Pfizer. 2024 Annual Review. Published March 13, 2025.
- The Patients Reached metric is calculated from Pfizer and third-party datasets. Figures may be limited given the coverage provided by external sources (e.g., calendar duration, geographic and product coverage) and are subject to change. Numbers are estimates and, in some cases, use global volume, daily dosage and number of treatment days to facilitate calculations. Methodologies to calculate estimates may vary by product type given the nature of the product and available data. Patients taking multiple Pfizer products may be counted as multiple patients toward the total. Numbers include estimated patient counts from our “Accord for a Healthier World” program. Numbers do not include comprehensive estimated patient counts from Ex-U.S. Patient Support Programs. Historical estimates may periodically be subject to revision due to restatements in the underlying data source.

















